Zacks Investment Research lowered shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) from a hold rating to a sell rating in a research report sent to investors on Friday.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Several other analysts have also commented on PSTI. HC Wainwright reaffirmed a buy rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a research note on Tuesday, September 19th. Maxim Group reaffirmed a buy rating and issued a $2.00 price target on shares of Pluristem Therapeutics in a research note on Tuesday, September 5th. Finally, ValuEngine lowered Pluristem Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $3.19.

Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at 1.54 on Friday. The firm has a 50-day moving average price of $1.20 and a 200 day moving average price of $1.28. The firm’s market capitalization is $150.11 million. Pluristem Therapeutics has a 12 month low of $1.04 and a 12 month high of $1.65.

WARNING: “Pluristem Therapeutics, Inc. (PSTI) Cut to “Sell” at Zacks Investment Research” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at

An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,553,800 shares of the biotechnology company’s stock after acquiring an additional 129,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Pluristem Therapeutics

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with's FREE daily email newsletter.